Keith Crandell - Net Worth and Insider Trading

Keith Crandell Net Worth

The estimated net worth of Keith Crandell is at least $246 Million dollars as of 2024-10-05. Keith Crandell is the 10% Owner of Alnylam Pharmaceuticals Inc and owns about 222,500 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $60 Million. Keith Crandell is the Director, 10% Owner of Quanterix Corp and owns about 3,949,685 shares of Quanterix Corp (QTRX) stock worth over $47 Million. Keith Crandell is also the 10% Owner of Sana Biotechnology Inc and owns about 10,301,250 shares of Sana Biotechnology Inc (SANA) stock worth over $44 Million. Besides these, Keith Crandell also holds DA32 Life Science Tech Acquisition Corp (DALS) , Twist Bioscience Corp (TWST) , 908 Devices Inc (MASS) , Boundless Bio Inc (BOLD) , Adesto Technologies Corp (IOTS) . Details can be seen in Keith Crandell's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Keith Crandell has not made any transactions after 2024-04-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Keith Crandell

Keith Crandell Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Keith Crandell owns 38 companies in total, including Codiak BioSciences Inc (CDAKQ) , Quanterix Corp (QTRX) , and Metacrine Inc (MTCR) among others .

Click here to see the complete history of Keith Crandell’s form 4 insider trades.

Insider Ownership Summary of Keith Crandell

Ticker	Comapny	Transaction Date	Type of Owner
CDAKQ	Codiak BioSciences Inc	2020-10-13	10 percent owner
QTRX	Quanterix Corp	2020-11-20	director & 10 percent owner
MTCR	Metacrine Inc	2020-09-15	10 percent owner
		2020-02-05	10 percent owner
		2021-08-12	director
		2021-03-30	10 percent owner
		2019-08-08	10 percent owner
		2019-03-07	10 percent owner
		2019-06-27	10 percent owner
		2019-06-04	director
		2018-03-27	10 percent owner
		2019-02-22	10 percent owner
		2019-02-07	10 percent owner
		2018-05-23	10 percent owner
		2018-05-02	10 percent owner
		2018-04-03	other: Former 10% owner
		2016-10-11	10 percent owner
		2016-07-20	10 percent owner
		2016-05-23	10 percent owner
		2016-03-15	10 percent owner
		2015-01-14	10 percent owner
		2014-06-23	10 percent owner
		2015-02-13	10 percent owner
		2014-03-17	10 percent owner
		2013-09-30	10 percent owner
		2013-06-18	10 percent owner
		2011-07-21	10 percent owner
		2004-10-29	10 percent owner
		2004-05-27	10 percent owner
		2003-11-26	10 percent owner
		2020-12-22	director & 10 percent owner
		2021-07-15	10 percent owner
		2024-02-08	10 percent owner
		2021-06-16	10 percent owner
		2021-06-16	10 percent owner
		2021-07-30	director & 10 percent owner
		2022-10-19	10 percent owner
		2023-09-14	10 percent owner

Keith Crandell Latest Holdings Summary

Keith Crandell currently owns a total of 8 stocks. Among these stocks, Keith Crandell owns 222,500 shares of Alnylam Pharmaceuticals Inc (ALNY) as of May 27, 2004, with a value of $60 Million and a weighting of 24.2%. Keith Crandell owns 3,949,685 shares of Quanterix Corp (QTRX) as of December 11, 2017, with a value of $47 Million and a weighting of 19.08%. Keith Crandell also owns 10,301,250 shares of Sana Biotechnology Inc (SANA) as of February 8, 2024, with a value of $44 Million and a weighting of 17.69%. The other 5 stocks DA32 Life Science Tech Acquisition Corp (DALS) , Twist Bioscience Corp (TWST) , 908 Devices Inc (MASS) , Boundless Bio Inc (BOLD) , Adesto Technologies Corp (IOTS) have a combined weighting of 39.03% among all his current holdings.

Latest Holdings of Keith Crandell

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ALNY	Alnylam Pharmaceuticals Inc	2004-05-27	222,500	267.99	59,627,775
QTRX	Quanterix Corp	2017-12-11	3,949,685	11.90	47,001,252
SANA	Sana Biotechnology Inc	2024-02-08	10,301,250	4.23	43,574,288
DALS	DA32 Life Science Tech Acquisition Corp	2021-07-30	3,850,000	10.32	39,732,000
TWST	Twist Bioscience Corp	2021-08-12	560,475	43.34	24,290,987
MASS	908 Devices Inc	2020-12-22	5,725,045	3.50	20,037,658
BOLD	Boundless Bio Inc	2024-04-02	2,230,199	3.18	7,092,033
IOTS	Adesto Technologies Corp	2015-10-26	400,000	12.54	5,016,000

Holding Weightings of Keith Crandell

Keith Crandell Form 4 Trading Tracker

According to the SEC Form 4 filings, Keith Crandell has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 0 shares on May 27, 2004, which brought Keith Crandell around $0.

According to the SEC Form 4 filings, Keith Crandell has made a total of 0 transactions in Quanterix Corp (QTRX) over the past 5 years. The most-recent trade in Quanterix Corp is the acquisition of 266,000 shares on December 11, 2017, which cost Keith Crandell around $4 Million.

According to the SEC Form 4 filings, Keith Crandell has made a total of 1 transactions in Sana Biotechnology Inc (SANA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Sana Biotechnology Inc is the acquisition of 1,818,181 shares on February 8, 2024, which cost Keith Crandell around $10 Million.

More details on Keith Crandell's insider transactions can be found in the Insider Trading History of Keith Crandell table.

Insider Trading History of Keith Crandell

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Keith Crandell Trading Performance

GuruFocus tracks the stock performance after each of Keith Crandell's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Keith Crandell is 6.2%. GuruFocus also compares Keith Crandell's trading performance to market benchmark return within the same time period. The performance of stocks bought by Keith Crandell within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Keith Crandell's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Keith Crandell

Average Return

Average return per transaction

Outperforming Transactions

2 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	21.49
Relative Return to S&P 500(%)	19.42

Keith Crandell Ownership Network

Ownership Network List of Keith Crandell

No Data

Ownership Network Relation of Keith Crandell

Keith Crandell Owned Company Details

What does Codiak BioSciences Inc do?

Who are the key executives at Codiak BioSciences Inc?

Keith Crandell is the 10 percent owner of Codiak BioSciences Inc. Other key executives at Codiak BioSciences Inc include See Remarks Yalonda Howze , Chief Scientific Officer Sriram Sathyanarayanan , and See Remarks Nicole Barna .

Codiak BioSciences Inc (CDAKQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Codiak BioSciences Inc (CDAKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Codiak BioSciences Inc (CDAKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Codiak BioSciences Inc (CDAKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Codiak BioSciences Inc Insider Transactions

No Available Data

What does Quanterix Corp do?

Who are the key executives at Quanterix Corp?

Keith Crandell is the director & 10 percent owner of Quanterix Corp. Other key executives at Quanterix Corp include President & Quanterix & Dx Masoud Toloue , Chief Financial Officer Vandana Sriram , and CFO and Treasurer Michael A Doyle .

Quanterix Corp (QTRX) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Quanterix Corp (QTRX). Other recent insider transactions involving Quanterix Corp (QTRX) include a net sale of 5,500 shares made by Laurie J Olson , a net purchase of 47,000 shares made by David R Walt , and a net purchase of 20,200 shares made by William P Donnelly .

In summary, during the past 3 months, insiders sold 0 shares of Quanterix Corp (QTRX) in total and bought 66,000 shares, with a net purchase of 66,000 shares. During the past 18 months, 5,500 shares of Quanterix Corp (QTRX) were sold and 86,200 shares were bought by its insiders, resulting in a net purchase of 80,700 shares.

Quanterix Corp (QTRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Quanterix Corp Insider Transactions

No Available Data

What does Metacrine Inc do?

Who are the key executives at Metacrine Inc?

Keith Crandell is the 10 percent owner of Metacrine Inc. Other key executives at Metacrine Inc include Chief Business Officer Michael York , director & President & CEO Preston Klassen , and 10 percent owner Braden Michael Leonard .

Metacrine Inc (MTCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Metacrine Inc (MTCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Metacrine Inc (MTCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Metacrine Inc (MTCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Metacrine Inc Insider Transactions

No Available Data

What does Beam Therapeutics Inc do?

Who are the key executives at Beam Therapeutics Inc?

Keith Crandell is the 10 percent owner of Beam Therapeutics Inc. Other key executives at Beam Therapeutics Inc include Chief Legal Officer Christine Bellon , director & CEO John M. Evans , and Chief Medical Officer Amy Simon .

Beam Therapeutics Inc (BEAM) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Beam Therapeutics Inc (BEAM). Other recent insider transactions involving Beam Therapeutics Inc (BEAM) include a net sale of 16,081 shares made by Christine Bellon , a net sale of 198,102 shares made by John M. Evans , and a net sale of 28,776 shares made by Amy Simon .

In summary, during the past 3 months, insiders sold 60,674 shares of Beam Therapeutics Inc (BEAM) in total and bought 0 shares, with a net sale of 60,674 shares. During the past 18 months, 1,311,323 shares of Beam Therapeutics Inc (BEAM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,311,323 shares.

Beam Therapeutics Inc (BEAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Beam Therapeutics Inc Insider Transactions

No Available Data

What does Twist Bioscience Corp do?

Who are the key executives at Twist Bioscience Corp?

Keith Crandell is the director of Twist Bioscience Corp. Other key executives at Twist Bioscience Corp include VP of Human Resources Paula Green , See Remarks Dennis Cho , and VP of Sales and Marketing Patrick John Finn .

Twist Bioscience Corp (TWST) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Twist Bioscience Corp (TWST). Other recent insider transactions involving Twist Bioscience Corp (TWST) include a net purchase of 3,561 shares made by Dennis Cho , a net sale of 35,978 shares made by Emily M. Leproust , and a net sale of 9,132 shares made by Paula Green .

In summary, during the past 3 months, insiders sold 46,906 shares of Twist Bioscience Corp (TWST) in total and bought 0 shares, with a net sale of 46,906 shares. During the past 18 months, 81,720 shares of Twist Bioscience Corp (TWST) were sold and 10,000 shares were bought by its insiders, resulting in a net sale of 71,720 shares.

Twist Bioscience Corp (TWST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Twist Bioscience Corp Insider Transactions

No Available Data

What does Vir Biotechnology Inc do?

Who are the key executives at Vir Biotechnology Inc?

Keith Crandell is the 10 percent owner of Vir Biotechnology Inc. Other key executives at Vir Biotechnology Inc include Chief Executive Officer Backer Marianne De , Chief Technology Officer Ann M. Hanly , and Chief Financial Officer Sung Lee .

Vir Biotechnology Inc (VIR) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Vir Biotechnology Inc (VIR). Other recent insider transactions involving Vir Biotechnology Inc (VIR) include a net sale of 1,635,897 shares made by Svf Endurance (cayman) Ltd , a net sale of 22,889 shares made by Phillip Pang , and a net sale of 55,500 shares made by George A Scangos .

In summary, during the past 3 months, insiders sold 12,190 shares of Vir Biotechnology Inc (VIR) in total and bought 0 shares, with a net sale of 12,190 shares. During the past 18 months, 1,848,486 shares of Vir Biotechnology Inc (VIR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,848,486 shares.

Vir Biotechnology Inc (VIR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vir Biotechnology Inc Insider Transactions

No Available Data

What does Denali Therapeutics Inc do?

Who are the key executives at Denali Therapeutics Inc?

Keith Crandell is the 10 percent owner of Denali Therapeutics Inc. Other key executives at Denali Therapeutics Inc include CFO and Treasurer Steve E. Krognes , COO and Secretary Alexander O. Schuth , and Chief Medical Officer Carole Ho .

Denali Therapeutics Inc (DNLI) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Denali Therapeutics Inc (DNLI). Other recent insider transactions involving Denali Therapeutics Inc (DNLI) include a net sale of 25,506 shares made by Vicki L Sato , a net sale of 93,768 shares made by Alexander O. Schuth , and a net sale of 54,249 shares made by Carole Ho .

In summary, during the past 3 months, insiders sold 73,507 shares of Denali Therapeutics Inc (DNLI) in total and bought 0 shares, with a net sale of 73,507 shares. During the past 18 months, 454,258 shares of Denali Therapeutics Inc (DNLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 454,258 shares.

Denali Therapeutics Inc (DNLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Denali Therapeutics Inc Insider Transactions

No Available Data

What does Syros Pharmaceuticals Inc do?

Who are the key executives at Syros Pharmaceuticals Inc?

Keith Crandell is the 10 percent owner of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include Chief Financial Officer Jason Haas , Chief Commercial Officer Chee Conley , and Chief Medical Officer David Roth .

Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Syros Pharmaceuticals Inc (SYRS). Other recent insider transactions involving Syros Pharmaceuticals Inc (SYRS) include a net sale of 30,523 shares made by David Roth , a net purchase of 904,977 shares made by Srinivas Akkaraju , and a net purchase of 100,000 shares made by Jason Haas .

In summary, during the past 3 months, insiders sold 0 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 200,000 shares, with a net purchase of 200,000 shares. During the past 18 months, 31,212 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 1,104,977 shares were bought by its insiders, resulting in a net purchase of 1,073,765 shares.

Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syros Pharmaceuticals Inc Insider Transactions

No Available Data

What does Karuna Therapeutics Inc do?

Who are the key executives at Karuna Therapeutics Inc?

Keith Crandell is the 10 percent owner of Karuna Therapeutics Inc. Other key executives at Karuna Therapeutics Inc include Chief Medical Officer Stephen K. Brannan , Chief Financial Officer Jason Parker Brown , and Chief Financial Officer Troy A. Ignelzi .

Karuna Therapeutics Inc (KRTX) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Karuna Therapeutics Inc (KRTX). Other recent insider transactions involving Karuna Therapeutics Inc (KRTX) include a net sale of 60,000 shares made by Stephen K. Brannan , a net sale of 41,429 shares made by Jeffrey M Jonas , and a net sale of 10,500 shares made by Troy A. Ignelzi .

In summary, during the past 3 months, insiders sold 0 shares of Karuna Therapeutics Inc (KRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 156,929 shares of Karuna Therapeutics Inc (KRTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 156,929 shares.

Karuna Therapeutics Inc (KRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Karuna Therapeutics Inc Insider Transactions

No Available Data

What does Adesto Technologies Corp do?

Who are the key executives at Adesto Technologies Corp?

Keith Crandell is the director of Adesto Technologies Corp. Other key executives at Adesto Technologies Corp include VP & Worldwide Sales Thomas D Spade , 10 percent owner Harris & Harris Group Inc /ny/ , and 10 percent owner Robert Nelsen .

Adesto Technologies Corp (IOTS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Adesto Technologies Corp (IOTS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Adesto Technologies Corp (IOTS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Adesto Technologies Corp (IOTS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adesto Technologies Corp Insider Transactions

No Available Data

What does Homology Medicines Inc do?

Who are the key executives at Homology Medicines Inc?

Keith Crandell is the 10 percent owner of Homology Medicines Inc. Other key executives at Homology Medicines Inc include director & President & CEO Arthur Tzianabos , See Remarks Paul Alloway , and Chief Scientific Officer Albert Seymour .

Homology Medicines Inc (FIXX) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Homology Medicines Inc (FIXX). Other recent insider transactions involving Homology Medicines Inc (FIXX) include a net sale of 1,952 shares made by Julie Jordan , a net sale of 13,037 shares made by Arthur Tzianabos , and a net sale of 7,280 shares made by Paul Alloway .

In summary, during the past 3 months, insiders sold 0 shares of Homology Medicines Inc (FIXX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,413 shares of Homology Medicines Inc (FIXX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,413 shares.

Homology Medicines Inc (FIXX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Homology Medicines Inc Insider Transactions

No Available Data

What does Sienna Biopharmaceuticals Inc do?

Who are the key executives at Sienna Biopharmaceuticals Inc?

Keith Crandell is the 10 percent owner of Sienna Biopharmaceuticals Inc. Other key executives at Sienna Biopharmaceuticals Inc include Chief Financial Officer Alexander Azoy , Chief Medical Officer Paul F. Lizzul , and director & President & CEO Iii Frederick Beddingfield .

Sienna Biopharmaceuticals Inc (SNNAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sienna Biopharmaceuticals Inc (SNNAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sienna Biopharmaceuticals Inc Insider Transactions

No Available Data

What does Gossamer Bio Inc do?

Who are the key executives at Gossamer Bio Inc?

Keith Crandell is the 10 percent owner of Gossamer Bio Inc. Other key executives at Gossamer Bio Inc include Chief Medical Officer Richard Aranda , director & Executive Chairman Faheem Hasnain , and Chief Financial Officer Bryan Giraudo .

Gossamer Bio Inc (GOSS) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Gossamer Bio Inc (GOSS). Other recent insider transactions involving Gossamer Bio Inc (GOSS) include a net purchase of 293,570 shares made by Bryan Giraudo , a net sale of 7,740 shares made by Richard Aranda , and a net purchase of 348,828 shares made by Faheem Hasnain .

In summary, during the past 3 months, insiders sold 0 shares of Gossamer Bio Inc (GOSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 47,790 shares of Gossamer Bio Inc (GOSS) were sold and 729,000 shares were bought by its insiders, resulting in a net purchase of 681,210 shares.

Gossamer Bio Inc (GOSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gossamer Bio Inc Insider Transactions

No Available Data

What does Scholar Rock Holding Corp do?

Who are the key executives at Scholar Rock Holding Corp?

Keith Crandell is the 10 percent owner of Scholar Rock Holding Corp. Other key executives at Scholar Rock Holding Corp include SVP and Head of Research Mo Qatanani , CHRO Caryn Parlavecchio , and General Counsel Junlin Ho .

Scholar Rock Holding Corp (SRRK) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Scholar Rock Holding Corp (SRRK). Other recent insider transactions involving Scholar Rock Holding Corp (SRRK) include a net sale of 93,216 shares made by Edward H Myles , a net sale of 35,372 shares made by Mo Qatanani , and a net sale of 13,709 shares made by Caryn Parlavecchio .

In summary, during the past 3 months, insiders sold 3,387 shares of Scholar Rock Holding Corp (SRRK) in total and bought 0 shares, with a net sale of 3,387 shares. During the past 18 months, 151,178 shares of Scholar Rock Holding Corp (SRRK) were sold and 6,611,050 shares were bought by its insiders, resulting in a net purchase of 6,459,872 shares.

Scholar Rock Holding Corp (SRRK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Scholar Rock Holding Corp Insider Transactions

No Available Data

What does Unity Biotechnology Inc do?

Who are the key executives at Unity Biotechnology Inc?

Keith Crandell is the 10 percent owner of Unity Biotechnology Inc. Other key executives at Unity Biotechnology Inc include See Remarks Lynne Marie Sullivan , director & Chief Executive Officer Anirvan Ghosh , and See Remarks Alexander Hieu Nguyen .

Unity Biotechnology Inc (UBX) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Unity Biotechnology Inc (UBX). Other recent insider transactions involving Unity Biotechnology Inc (UBX) include a net sale of 11,558 shares made by Anirvan Ghosh , a net sale of 463 shares made by Lynne Marie Sullivan , and a net sale of 232 shares made by Alexander Hieu Nguyen .

In summary, during the past 3 months, insiders sold 897 shares of Unity Biotechnology Inc (UBX) in total and bought 0 shares, with a net sale of 897 shares. During the past 18 months, 12,253 shares of Unity Biotechnology Inc (UBX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 12,253 shares.

Unity Biotechnology Inc (UBX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Unity Biotechnology Inc Insider Transactions

No Available Data

What does Pulmatrix Inc do?

Who are the key executives at Pulmatrix Inc?

Keith Crandell is the other: Former 10% owner of Pulmatrix Inc. Other key executives at Pulmatrix Inc include Interim CFO Peter Ludlum , Chief Medical Officer Margaret Wasilewski , and Vice President & Finance Michelle Siegert .

Pulmatrix Inc (PULM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pulmatrix Inc (PULM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pulmatrix Inc (PULM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pulmatrix Inc (PULM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pulmatrix Inc Insider Transactions

No Available Data

What does Xtera Communications Inc do?

Who are the key executives at Xtera Communications Inc?

Keith Crandell is the 10 percent owner of Xtera Communications Inc. Other key executives at Xtera Communications Inc include 10 percent owner Arch Venture Partners Vi Llc , 10 percent owner Robert Nelsen , and director & 10 percent owner Clinton Bybee .

Xtera Communications Inc (XCOMQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Xtera Communications Inc (XCOMQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Xtera Communications Inc (XCOMQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Xtera Communications Inc (XCOMQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Xtera Communications Inc Insider Transactions

No Available Data

What does Impinj Inc do?

Who are the key executives at Impinj Inc?

Keith Crandell is the 10 percent owner of Impinj Inc. Other key executives at Impinj Inc include Chief Financial Officer Cary Baker , Chief Operating Officer Hussein Mecklai , and EVP & Sales & Marketing Jeffrey Dossett .

Impinj Inc (PI) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Impinj Inc (PI). Other recent insider transactions involving Impinj Inc (PI) include a net sale of 81,583 shares made by Jeffrey Dossett , a net sale of 143,301 shares made by Diorio Chris Ph.d. , and a net sale of 49,314 shares made by Cary Baker .

In summary, during the past 3 months, insiders sold 45,242 shares of Impinj Inc (PI) in total and bought 4,264,393 shares, with a net purchase of 4,219,151 shares. During the past 18 months, 1,364,432 shares of Impinj Inc (PI) were sold and 5,763,587 shares were bought by its insiders, resulting in a net purchase of 4,399,155 shares.

Impinj Inc (PI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Impinj Inc Insider Transactions

No Available Data

What does PhaseRx Inc do?

Who are the key executives at PhaseRx Inc?

Keith Crandell is the 10 percent owner of PhaseRx Inc. Other key executives at PhaseRx Inc include Chief Medical Officer Gordon Brandt , director & 10 percent owner Steven Gillis , and director & 10 percent owner Brian G Atwood .

PhaseRx Inc (PZRXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PhaseRx Inc (PZRXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhaseRx Inc (PZRXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PhaseRx Inc (PZRXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

PhaseRx Inc Insider Transactions

No Available Data

What does Juno Therapeutics Inc do?

Who are the key executives at Juno Therapeutics Inc?

Keith Crandell is the 10 percent owner of Juno Therapeutics Inc. Other key executives at Juno Therapeutics Inc include director & CEO & President Hans Edgar Bishop , 10 percent owner Celgene Corp /de/ , and 10 percent owner Celgene Switzerland Llc .

Juno Therapeutics Inc (JUNO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Juno Therapeutics Inc (JUNO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Juno Therapeutics Inc (JUNO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Juno Therapeutics Inc (JUNO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Juno Therapeutics Inc Insider Transactions

No Available Data

What does Sage Therapeutics Inc do?

Who are the key executives at Sage Therapeutics Inc?

Keith Crandell is the 10 percent owner of Sage Therapeutics Inc. Other key executives at Sage Therapeutics Inc include director & See Remarks Jeffrey M Jonas , Chief Medical Officer Laura Gault , and Chief Commercial Officer Christopher Benecchi .

Sage Therapeutics Inc (SAGE) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Sage Therapeutics Inc (SAGE). Other recent insider transactions involving Sage Therapeutics Inc (SAGE) include a net purchase of 3,000 shares made by Elizabeth Barrett ,

In summary, during the past 3 months, insiders sold 0 shares of Sage Therapeutics Inc (SAGE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sage Therapeutics Inc (SAGE) were sold and 3,000 shares were bought by its insiders, resulting in a net purchase of 3,000 shares.

Sage Therapeutics Inc (SAGE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sage Therapeutics Inc Insider Transactions

No Available Data

What does Agios Pharmaceuticals Inc do?

Who are the key executives at Agios Pharmaceuticals Inc?

Keith Crandell is the 10 percent owner of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Financial Officer Cecilia Jones , director & Chief Executive Officer Brian Goff , and Chief Medical Officer Sarah Gheuens .

Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Agios Pharmaceuticals Inc (AGIO). Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 9,416 shares made by Washburn Theodore James Jr. , a net sale of 64,534 shares made by Brian Goff , and a net sale of 14,160 shares made by James William Burns .

In summary, during the past 3 months, insiders sold 13,633 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 13,633 shares. During the past 18 months, 252,596 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 252,596 shares.

Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agios Pharmaceuticals Inc Insider Transactions

No Available Data

What does Bellerophon Therapeutics Inc do?

Who are the key executives at Bellerophon Therapeutics Inc?

Keith Crandell is the 10 percent owner of Bellerophon Therapeutics Inc. Other key executives at Bellerophon Therapeutics Inc include 10 percent owner Puissance Life Science Opportunities Fund Vi , VP of Business Operations Parag Suresh Shah , and See Remarks Martin Dekker .

Bellerophon Therapeutics Inc (BLPH) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Bellerophon Therapeutics Inc (BLPH). Other recent insider transactions involving Bellerophon Therapeutics Inc (BLPH) include a net sale of 694,421 shares made by Puissance Capital Fund (gp) Llc , a net sale of 1,076,841 shares made by Puissance Life Science Opportunities Fund Vi , and a net sale of 9,455 shares made by Bobae Kim .

In summary, during the past 3 months, insiders sold 0 shares of Bellerophon Therapeutics Inc (BLPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,780,717 shares of Bellerophon Therapeutics Inc (BLPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,780,717 shares.

Bellerophon Therapeutics Inc (BLPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bellerophon Therapeutics Inc Insider Transactions

No Available Data

What does Achaogen Inc do?

Who are the key executives at Achaogen Inc?

Keith Crandell is the 10 percent owner of Achaogen Inc. Other key executives at Achaogen Inc include 10 percent owner Robert W Duggan , Chief Operating Officer Elizabeth Bhatt , and See Remarks Gary Loeb .

Achaogen Inc (AKAOQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achaogen Inc (AKAOQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achaogen Inc (AKAOQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achaogen Inc (AKAOQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achaogen Inc Insider Transactions

No Available Data

What does Fate Therapeutics Inc do?

Who are the key executives at Fate Therapeutics Inc?

Keith Crandell is the 10 percent owner of Fate Therapeutics Inc. Other key executives at Fate Therapeutics Inc include Chief Financial Officer Dulac Edward J Iii , director & President and CEO J Scott Wolchko , and Chief Development Officer Bahram Valamehr .

Fate Therapeutics Inc (FATE) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Fate Therapeutics Inc (FATE). Other recent insider transactions involving Fate Therapeutics Inc (FATE) include a net purchase of 44,630 shares made by Redmile Group, Llc , a net sale of 18,777 shares made by Dulac Edward J Iii , and a net sale of 4,725 shares made by Yuan Xu .

In summary, during the past 3 months, insiders sold 633 shares of Fate Therapeutics Inc (FATE) in total and bought 0 shares, with a net sale of 633 shares. During the past 18 months, 393,126 shares of Fate Therapeutics Inc (FATE) were sold and 346,969 shares were bought by its insiders, resulting in a net sale of 46,157 shares.

Fate Therapeutics Inc (FATE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fate Therapeutics Inc Insider Transactions

No Available Data

What does bluebird bio Inc do?

Who are the key executives at bluebird bio Inc?

Keith Crandell is the 10 percent owner of bluebird bio Inc. Other key executives at bluebird bio Inc include Chief Commercial Officer & SGD Thomas J Klima , President of SGD Andrew Obenshain , and Chief Medical Officer Richard A Colvin .

bluebird bio Inc (BLUE) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in bluebird bio Inc (BLUE). Other recent insider transactions involving bluebird bio Inc (BLUE) include a net sale of 28,872 shares made by Andrew Obenshain , a net sale of 16,173 shares made by Thomas J Klima , and a net sale of 9,710 shares made by Richard A Colvin .

In summary, during the past 3 months, insiders sold 0 shares of bluebird bio Inc (BLUE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 64,498 shares of bluebird bio Inc (BLUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 64,498 shares.

bluebird bio Inc (BLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

bluebird bio Inc Insider Transactions

No Available Data

What does NeurogesX Inc do?

Who are the key executives at NeurogesX Inc?

Keith Crandell is the 10 percent owner of NeurogesX Inc. Other key executives at NeurogesX Inc include President and CEO Ron Martell , Exec. V.P. & COO & CFO Stephen F Ghiglieri , and director & 10 percent owner Robert Nelsen .

NeurogesX Inc (NGSX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NeurogesX Inc (NGSX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NeurogesX Inc (NGSX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NeurogesX Inc (NGSX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeurogesX Inc Insider Transactions

No Available Data

What does Cyclacel Pharmaceuticals Inc do?

Who are the key executives at Cyclacel Pharmaceuticals Inc?

Keith Crandell is the 10 percent owner of Cyclacel Pharmaceuticals Inc. Other key executives at Cyclacel Pharmaceuticals Inc include director & President & C.E.O. Spiro Rombotis , director & E.V.P. & Finance & C.O.O. Paul Mcbarron , and Chief Medical Officer Mark Kirschbaum .

Cyclacel Pharmaceuticals Inc (CYCC) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Cyclacel Pharmaceuticals Inc (CYCC). Other recent insider transactions involving Cyclacel Pharmaceuticals Inc (CYCC) include a net purchase of 6,070 shares made by Spiro Rombotis , and a net purchase of 1,886 shares made by Paul Mcbarron .

In summary, during the past 3 months, insiders sold 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) were sold and 7,956 shares were bought by its insiders, resulting in a net purchase of 7,956 shares.

Cyclacel Pharmaceuticals Inc (CYCC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cyclacel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Alnylam Pharmaceuticals Inc do?

Who are the key executives at Alnylam Pharmaceuticals Inc?

Keith Crandell is the 10 percent owner of Alnylam Pharmaceuticals Inc. Other key executives at Alnylam Pharmaceuticals Inc include EVP & Chief Commercial Officer Yvonne Greenstreet , EVP & Chief Commercial Officer Tolga Tanguler , and CMO & EVP Dev & Med Affairs Pushkal Garg .

Alnylam Pharmaceuticals Inc (ALNY) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Alnylam Pharmaceuticals Inc (ALNY). Other recent insider transactions involving Alnylam Pharmaceuticals Inc (ALNY) include a net sale of 60,146 shares made by Yvonne Greenstreet , a net sale of 14,598 shares made by Pushkal Garg , and a net sale of 6,616 shares made by Jeffrey V. Poulton .

In summary, during the past 3 months, insiders sold 79,516 shares of Alnylam Pharmaceuticals Inc (ALNY) in total and bought 0 shares, with a net sale of 79,516 shares. During the past 18 months, 269,382 shares of Alnylam Pharmaceuticals Inc (ALNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 269,382 shares.

Alnylam Pharmaceuticals Inc (ALNY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alnylam Pharmaceuticals Inc Insider Transactions

No Available Data

What does Illumina Inc do?

Who are the key executives at Illumina Inc?

Keith Crandell is the 10 percent owner of Illumina Inc. Other key executives at Illumina Inc include director & Chief Executive Officer Jacob Thaysen , SVP & Chief People Officer Aimee L Hoyt , and SVP Product Development Susan H Tousi .

Illumina Inc (ILMN) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Illumina Inc (ILMN). Other recent insider transactions involving Illumina Inc (ILMN) include a net sale of 6,500 shares made by Susan H Tousi , a net purchase of 7,330 shares made by Jacob Thaysen , and a net sale of 315 shares made by Aimee L Hoyt .

In summary, during the past 3 months, insiders sold 0 shares of Illumina Inc (ILMN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,815 shares of Illumina Inc (ILMN) were sold and 7,330 shares were bought by its insiders, resulting in a net purchase of 515 shares.

Illumina Inc (ILMN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Illumina Inc Insider Transactions

No Available Data

What does 908 Devices Inc do?

Who are the key executives at 908 Devices Inc?

Keith Crandell is the director & 10 percent owner of 908 Devices Inc. Other key executives at 908 Devices Inc include director & President and CEO Kevin J. Knopp , Chief Financial Officer Griffith Joseph H. Iv , and VP & General Counsel Michael S. Turner .

908 Devices Inc (MASS) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in 908 Devices Inc (MASS). Other recent insider transactions involving 908 Devices Inc (MASS) include a net sale of 19,071 shares made by Kevin J. Knopp , a net sale of 38,427 shares made by Christopher D. Brown , and a net sale of 26,989 shares made by Griffith Joseph H. Iv .

In summary, during the past 3 months, insiders sold 0 shares of 908 Devices Inc (MASS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 139,719 shares of 908 Devices Inc (MASS) were sold and 50,000 shares were bought by its insiders, resulting in a net sale of 89,719 shares.

908 Devices Inc (MASS)'s detailed insider trading history can be found in Insider Trading Tracker table.

908 Devices Inc Insider Transactions

No Available Data

What does Erasca Inc do?

Who are the key executives at Erasca Inc?

Keith Crandell is the 10 percent owner of Erasca Inc. Other key executives at Erasca Inc include director & 10 percent owner & See Remarks Jonathan E Lim , Chief Medical Officer Shannon Morris , and General Counsel Ebun Garner .

Erasca Inc (ERAS) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Erasca Inc (ERAS). Other recent insider transactions involving Erasca Inc (ERAS) include a net purchase of 2,100,000 shares made by Jonathan E Lim , a net purchase of 130,000 shares made by Alexander W. Casdin , and a net purchase of 10,000 shares made by Start Valerie Denise Harding .

In summary, during the past 3 months, insiders sold 0 shares of Erasca Inc (ERAS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Erasca Inc (ERAS) were sold and 2,240,000 shares were bought by its insiders, resulting in a net purchase of 2,240,000 shares.

Erasca Inc (ERAS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Erasca Inc Insider Transactions

No Available Data

What does Sana Biotechnology Inc do?

Who are the key executives at Sana Biotechnology Inc?

Keith Crandell is the 10 percent owner of Sana Biotechnology Inc. Other key executives at Sana Biotechnology Inc include director & Head of SanaX Richard Mulligan , 10 percent owner Arch Venture Fund X Overage, L.p. , and SVP & Chief Business Officer Christian Hordo .

Sana Biotechnology Inc (SANA) Insider Trades Summary

Over the past 18 months, Keith Crandell made 1 insider transaction in Sana Biotechnology Inc (SANA) with a net purchase of 1,818,181. Other recent insider transactions involving Sana Biotechnology Inc (SANA) include a net sale of 949,000 shares made by Flagship Ventures Fund V, L.p. , a net purchase of 1,818,181 shares made by Robert Nelsen , and a net purchase of 1,818,181 shares made by Arch Venture Fund X Overage, L.p. .

In summary, during the past 3 months, insiders sold 300,000 shares of Sana Biotechnology Inc (SANA) in total and bought 0 shares, with a net sale of 300,000 shares. During the past 18 months, 1,349,000 shares of Sana Biotechnology Inc (SANA) were sold and 5,454,543 shares were bought by its insiders, resulting in a net purchase of 4,105,543 shares.

Sana Biotechnology Inc (SANA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sana Biotechnology Inc Insider Transactions

No Available Data

What does Lyell Immunopharma Inc do?

Who are the key executives at Lyell Immunopharma Inc?

Keith Crandell is the 10 percent owner of Lyell Immunopharma Inc. Other key executives at Lyell Immunopharma Inc include director & Executive Chairman Richard Klausner , Chief Business Officer Matthew Lang , and Chief Legal Officer Rahsaan Thompson .

Lyell Immunopharma Inc (LYEL) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Lyell Immunopharma Inc (LYEL). Other recent insider transactions involving Lyell Immunopharma Inc (LYEL) include a net sale of 58,020 shares made by Richard Klausner ,

In summary, during the past 3 months, insiders sold 0 shares of Lyell Immunopharma Inc (LYEL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 58,020 shares of Lyell Immunopharma Inc (LYEL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 58,020 shares.

Lyell Immunopharma Inc (LYEL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Lyell Immunopharma Inc Insider Transactions

No Available Data

What does Verve Therapeutics Inc do?

Who are the key executives at Verve Therapeutics Inc?

Keith Crandell is the 10 percent owner of Verve Therapeutics Inc. Other key executives at Verve Therapeutics Inc include See Remarks Andrew D. Ashe , Chief Administrative Officer Joan Nickerson , and director & 10 percent owner Krishna Yeshwant .

Verve Therapeutics Inc (VERV) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Verve Therapeutics Inc (VERV). Other recent insider transactions involving Verve Therapeutics Inc (VERV) include a net purchase of 1,800,000 shares made by Krishna Yeshwant , a net purchase of 76,000 shares made by Andrew D. Ashe , and a net sale of 1,514 shares made by Joan Nickerson .

In summary, during the past 3 months, insiders sold 0 shares of Verve Therapeutics Inc (VERV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,068 shares of Verve Therapeutics Inc (VERV) were sold and 1,876,000 shares were bought by its insiders, resulting in a net purchase of 1,873,932 shares.

Verve Therapeutics Inc (VERV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verve Therapeutics Inc Insider Transactions

No Available Data

What does DA32 Life Science Tech Acquisition Corp do?

Who are the key executives at DA32 Life Science Tech Acquisition Corp?

Keith Crandell is the director & 10 percent owner of DA32 Life Science Tech Acquisition Corp. Other key executives at DA32 Life Science Tech Acquisition Corp include director & 10 percent owner & other: Director by deputization Deerfield Management Company, L.p. (series C) , 10 percent owner & other: Director by Deputization Section 32 Fund 3, Lp , and 10 percent owner Arch Venture Fund Xi, L.p. .

DA32 Life Science Tech Acquisition Corp (DALS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of DA32 Life Science Tech Acquisition Corp (DALS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of DA32 Life Science Tech Acquisition Corp (DALS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

DA32 Life Science Tech Acquisition Corp (DALS)'s detailed insider trading history can be found in Insider Trading Tracker table.

DA32 Life Science Tech Acquisition Corp Insider Transactions

No Available Data

What does Prime Medicine Inc do?

Who are the key executives at Prime Medicine Inc?

Keith Crandell is the 10 percent owner of Prime Medicine Inc. Other key executives at Prime Medicine Inc include 10 percent owner Arch Venture Partners X, Llc , director & 10 percent owner Robert Nelsen , and 10 percent owner Gv 2019 Gp, L.l.c. .

Prime Medicine Inc (PRME) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Prime Medicine Inc (PRME). Other recent insider transactions involving Prime Medicine Inc (PRME) include a net sale of 1,422,190 shares made by Gv 2019 Gp, L.l.c. , a net purchase of 3,200,000 shares made by Arch Venture Partners Xii, Llc , and a net purchase of 3,200,000 shares made by Robert Nelsen .

In summary, during the past 3 months, insiders sold 0 shares of Prime Medicine Inc (PRME) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,422,190 shares of Prime Medicine Inc (PRME) were sold and 9,600,000 shares were bought by its insiders, resulting in a net purchase of 8,177,810 shares.

Prime Medicine Inc (PRME)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prime Medicine Inc Insider Transactions

No Available Data

What does Neumora Therapeutics Inc do?

Who are the key executives at Neumora Therapeutics Inc?

Keith Crandell is the 10 percent owner of Neumora Therapeutics Inc. Other key executives at Neumora Therapeutics Inc include Head of R&D Robert A. Lenz , Chief Financial Officer Joshua Pinto , and 10 percent owner Arch Venture Partners Xii, Llc .

Neumora Therapeutics Inc (NMRA) Insider Trades Summary

Over the past 18 months, Keith Crandell made no insider transaction in Neumora Therapeutics Inc (NMRA). Other recent insider transactions involving Neumora Therapeutics Inc (NMRA) include a net purchase of 2,007,064 shares made by Kristina Burow , a net purchase of 507,064 shares made by Arch Venture Partners Xii, Llc , and a net sale of 100,000 shares made by Joshua Pinto .

In summary, during the past 3 months, insiders sold 174,412 shares of Neumora Therapeutics Inc (NMRA) in total and bought 0 shares, with a net sale of 174,412 shares. During the past 18 months, 174,412 shares of Neumora Therapeutics Inc (NMRA) were sold and 7,293,833 shares were bought by its insiders, resulting in a net purchase of 7,119,421 shares.

Neumora Therapeutics Inc (NMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neumora Therapeutics Inc Insider Transactions

No Available Data

Keith Crandell Mailing Address

Above is the net worth, insider trading, and ownership report for Keith Crandell. You might contact Keith Crandell via mailing address: 8755 W. Higgins Road, Suite 1025, Chicago Il 60631.

Discussions on Keith Crandell

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.